New Drugs

FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14

5 years ago
by David Miller
952 Views
Written by David Miller

EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]